ConductScience.org, home

Paper32749941

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

León-Castillo A and 22 others. J Clin Oncol, 2020. Cited by 686 papers, by iCite.

Cite this record

ConductScience Library. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Papers, record 32749941. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32749941

Download JSON
Disease
endometrial cancer242 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
PubMed
Journal
J Clin Oncol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
686
iCite
Relative citation ratio, by iCite
32.8
iCite
Revised in PubMed
2025-05-30
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1León-Castillo AAlicia
2de Boer SMStephanie M
3Powell MEMelanie E
4Mileshkin LRLinda R
5Mackay HJHelen J
6Leary AAlexandra
7Nijman HWHans W
8Singh NNaveena
9Pollock PMPamela M
10Bessette PPaul
11Fyles AAnthony
12Haie-Meder CChristine
13Smit VTHBMVincent T H B M
14Edmondson RJRichard J
15Putter HHein
16Kitchener HCHenry C
17Crosbie EJEmma J
18de Bruyn MMarco
19Nout RARemi A
20Horeweg NNanda

Source PubMed

See all 23 authorsDownload CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Endometrial NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Chemoradiotherapy, Adjuvant
DNA Mismatch Repair
DNA Polymerase II
DNA-Binding Proteins
Female
Humans
Immunohistochemistry
Middle Aged
Paraffin Embedding
Poly-ADP-Ribose Binding Proteins
Prognosis
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Tumor Suppressor Protein p53

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
8659Cancer Research UKUnited KingdomPubMed
NIHR-CS-012-009Department of HealthUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00411138Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial CancerResultsYesClinicalTrials.gov
NCT05179447PROfiling Based Endometrial Cancer Adjuvant TherapyBackgroundClinicalTrials.gov
NCT05955079Circulating Tumor DNA Study in Patients With Endometrial CancerBackgroundClinicalTrials.gov
NCT06680791Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle FactorsBackgroundClinicalTrials.gov

Download CSV of trials

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131846532Incorporation of molecular characteristics into endometrial cancer management.Histopathology2020https://conductscience.org/library/papers/31846532PubMed
228061006Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Cancer2017https://conductscience.org/library/papers/28061006PubMed
327397040Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol2016https://conductscience.org/library/papers/27397040PubMed
431492746Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity.Clin Cancer Res2019https://conductscience.org/library/papers/31492746PubMed
531829447Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.J Pathol2020https://conductscience.org/library/papers/31829447PubMed
629449189Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.Lancet Oncol2018https://conductscience.org/library/papers/29449189PubMed
722750048Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis.Exp Mol Pathol2013https://conductscience.org/library/papers/22750048PubMed
830864976Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.Am J Surg Pathol2019https://conductscience.org/library/papers/30864976PubMed
931829441p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.J Pathol2020https://conductscience.org/library/papers/31829441PubMed
1027742654Practical guidance for mismatch repair-deficiency testing in endometrial cancer.Ann Oncol2017https://conductscience.org/library/papers/27742654PubMed
1129584549Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.J Clin Oncol2018https://conductscience.org/library/papers/29584549PubMed
1231682550Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol2020https://conductscience.org/library/papers/31682550PubMed
1331829442Interpretation of somatic POLE mutations in endometrial carcinoma.J Pathol2020https://conductscience.org/library/papers/31829442PubMed
1431103324Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.Gynecol Oncol2019https://conductscience.org/library/papers/31103324PubMed
1524576030HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.Arch Pathol Lab Med2014https://conductscience.org/library/papers/24576030PubMed
1629190319Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.Ann Oncol2018https://conductscience.org/library/papers/29190319PubMed
1731345626Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/31345626PubMed
1823629444Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.Am J Surg Pathol2013https://conductscience.org/library/papers/23629444PubMed
1929432521Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.Ann Oncol2018https://conductscience.org/library/papers/29432521PubMed
2030995174Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.J Clin Oncol2019https://conductscience.org/library/papers/30995174PubMed

See all 31 referencesDownload CSV of references

Cited by401

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 686 citations.

PMIDTitleJournalYearIn PapersSource
42988877Evaluation of the Idylla system for rapid detection of POLE mutations in colorectal and endometrial cancers.Virchows Arch2026https://conductscience.org/library/papers/42988877PubMed
42959168Case Report: Endometrial carcinoma harboring a rare POLE p.T278K variant and dual MSH6 frameshift variants.Front Oncol2026https://conductscience.org/library/papers/42959168PubMed
42947969Spatial lipidomics in gynecologic malignancies: molecular identification, cellular attribution, and mechanistic validation.Front Mol Biosci2026https://conductscience.org/library/papers/42947969PubMed
42941666Beyond Molecular Classification: The Incremental Value of Prognostic Biomarkers in Endometrial Cancer.J Clin Med2026https://conductscience.org/library/papers/42941666PubMed
42938851Integrated Molecular Classification of Endometrial Cancer: Impact on Diagnosis, Prognosis, and Clinical Management-A Systematic Review.Cancers (Basel)2026https://conductscience.org/library/papers/42938851PubMed
42930168Targeted Hotspot Mutation Analysis of KRAS, TP53, and PTEN in Endometrial Cancer Revealed by Next-Generation Sequencing.Curr Oncol2026https://conductscience.org/library/papers/42930168PubMed
42898997Endometrial cancer molecular classification: research advances and clinical application.Front Oncol2026https://conductscience.org/library/papers/42898997PubMed
42886889PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.JCO Precis Oncol2026https://conductscience.org/library/papers/42886889PubMed
42883850Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer-Systematic Review.Int J Mol Sci2026https://conductscience.org/library/papers/42883850PubMed
42882917Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management.Cancers (Basel)2026https://conductscience.org/library/papers/42882917PubMed
42851344Advanced endometrial cancer in the gulf cooperation council: a modified-Delphi consensus on unmet needs, molecular testing, and treatment sequencing.Front Oncol2026https://conductscience.org/library/papers/42851344PubMed
42848197[Combination of radiotherapy and medicinal anticancer therapy with curative intent].Radiologie (Heidelb)2026https://conductscience.org/library/papers/42848197PubMed
42812477Impact of molecular profiling in patients with endometrial cancer: real world experience from India.Front Oncol2026https://conductscience.org/library/papers/42812477PubMed
42793688Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review.Diagnostics (Basel)2026https://conductscience.org/library/papers/42793688PubMed
42755952Oncologic safety of sentinel lymph node-based nodal de-escalation in apparent uterine-confined endometrial cancer: a multicenter international cohort study.Front Oncol2026https://conductscience.org/library/papers/42755952PubMed
42738293Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions.Cancers (Basel)2026https://conductscience.org/library/papers/42738293PubMed
42720254p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay.Mol Oncol2026https://conductscience.org/library/papers/42720254PubMed
42706566The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology.World J Surg Oncol2026https://conductscience.org/library/papers/42706566PubMed
42661600
Microcystic, elongated, and fragmented (MELF) pattern of myometrial invasion in grade 1-2 endometrioid endometrial carcinoma: clinicopathological associations, molecular profile, and prognostic significance under FIGO 2023 staging.
Front Oncol2026https://conductscience.org/library/papers/42661600PubMed
42658373Current Treatment Options Guided by Molecular Classification in Endometrial Cancer.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42658373PubMed

See all 401 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Results1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
CARBOPLATINCHEMBL1351Results1https://conductscience.org/library/drugs/CHEMBL1351ChEMBL
PACLITAXELCHEMBL428647Results1https://conductscience.org/library/drugs/CHEMBL428647ChEMBL

Download CSV of drugs

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
ISRCTNISRCTN14387080

Source ISRCTN

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32749941

GET https://conductscience.org/api/papers/v1/32749941/authors?page=2